• FDA Approves Evoxac (cevimeline HCl) Oral Solution for Dry Mouth Symptoms Associated with Sjögren’s Disease in Adults

  On October 20, 2026, local time, Cosette announced that the U.S. FDA has approved Evoxac(cevimeline HCl) oral solution for the treatment of dry mouth ···【Read More】

  Update: 23 Oct,2026Source: BigbearViews: 111

• U.S. FDA Approves Hovilpri (pritelivir) for the Treatment of Refractory Mucocutaneous HSV Lesions in Immunocompromised Adults

  On October 10, 2026, local time, the U.S. FDA approved Hovilpri (pritelivir) 100 mg tablets for the treatment of mucocutaneous lesions caused by herpe···【Read More】

  Update: 21 Oct,2026Source: BigbearViews: 120

• Anktiva Indication Expanded! U.S. FDA Approves It for Treatment of Some Patients with BCG-Unresponsive Bladder Cancer

  Recently, the U.S. Food and Drug Administration (FDA) expanded the approved indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination ···【Read More】

  Update: 19 Oct,2026Source: BigbearViews: 124

• Telisotuzumab Adizutecan (Temab-A) Receives Two U.S. FDA Breakthrough Therapy Designations for CRC and NSCLC

  On October 7, 2026, local time, AbbVie announced that the U.S. FDA has granted telisotuzumab adizutecan (Temab-A; ABBV-400) two breakthrough therapy d···【Read More】

  Update: 13 Oct,2026Source: BigbearViews: 155

• Study Suggests Laughter May Help Treat Chronic Obstructive Pulmonary Disease (COPD)

  A new study indicates that for patients with chronic obstructive pulmonary disease (COPD), “laughter therapy” is comparable to the classic “pursed-lip···【Read More】

  Update: 20 Sep,2026Source: BigbearViews: 211

• U.S. FDA Approves Ameluz Red-Light PDT for the Treatment of Superficial Basal Cell Carcinoma

  On September 14, 2026, local time, Biofrontera Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug ···【Read More】

  Update: 17 Sep,2026Source: BigbearViews: 243

• FDA Approves Isembyld (apitegromab-mstn) Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

  Recently, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca's Etcamah (camizestrant) in combination with···【Read More】

  Update: 15 Sep,2026Source: BigbearViews: 225

• Remibrutinib Significantly Reduces Relapse Rate and Shows Favorable Safety in Phase III Trial for New Indication in Relapsing Multiple Sclerosis (RMS)

  On September 1, 2026, local time, Novartis announced positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in rel···【Read More】

  Update: 07 Sep,2026Source: BigbearViews: 244

• Zanvastro (zilganersen) Approved in the U.S. for the Treatment of Rare Alexander Disease

  On September 3, 2026, the U.S. Food and Drug Administration (FDA) approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in···【Read More】

  Update: 04 Sep,2026Source: BigbearViews: 194

• FDA has approved Lytenava (bevacizumab-vikg) for neovascular age-related macular degeneration (nAMD)

  On July 24, 2026 local time, Outlook Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Lytenava (bevacizumab-···【Read More】

  Update: 03 Aug,2026Source: BigbearViews: 193

• FDA approves Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease!

  Local time June 26, 2026, Viridian Therapeutics, Inc., a biotechnology company focused on discovering, developing, and commercializing potential best-···【Read More】

  Update: 01 Jul,2026Source: BigbearViews: 267

• Sanofi’s Tzield Approved in the US as the First Disease-Modifying Therapy for Patients Recently Diagnosed with Stage 3 Type 1 Diabetes

  Paris, June 13, 2026. The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in e···【Read More】

  Update: 16 Jun,2026Source: BigbearViews: 333

• FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease

  On 15 May 2026, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) and atezolizumab and hyaluronidase-tqjs (···【Read More】

  Update: 12 Jun,2026Source: BigbearViews: 350

• FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

  June 9, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for EBGLYSS (lebriki···【Read More】

  Update: 10 Jun,2026Source: BigbearViews: 338

• Autobahn accelerates toward pivotal clinical trials: Thyroid hormone mimetic relieves bipolar depression in phase 2 trial

  Elunetirom is a small molecule drug taken orally once daily. After six weeks of treatment, patients' depression severity decreased by an average o···【Read More】

  Update: 05 Jun,2026Source: BigbearViews: 304